Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1056/NEJMoa2031994 http://scihub22266oqcxt.onion/10.1056/NEJMoa2031994 33306283!7745180!33306283     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       N+Engl+J+Med 2021 ; 384 (9): 795-807 Nephropedia Template TP {{tp|p=33306283|t=2021. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 |pdf=|usr=}}{{33306283}} gab.com Text Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 JO: N Engl J Med http://www.kidney.de/pget.php?&tw=1&pmid=33306283 #FOAvip BACKGROUND: Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. METHODS: We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (</=10 days) and either baricitinib (</=14 days) or placebo (control). The primary outcome was the time to recovery. The key secondary outcome was clinical status at day 15. RESULTS: A total of 1033 patients underwent randomization (with 515 assigned to combination treatment and 518 to control). Patients receiving baricitinib had a median time to recovery of 7 days (95% confidence interval [CI], 6 to 8), as compared with 8 days (95% CI, 7 to 9) with control (rate ratio for recovery, 1.16; 95% CI, 1.01 to 1.32; P = 0.03), and a 30% higher odds of improvement in clinical status at day 15 (odds ratio, 1.3; 95% CI, 1.0 to 1.6). Patients receiving high-flow oxygen or noninvasive ventilation at enrollment had a time to recovery of 10 days with combination treatment and 18 days with control (rate ratio for recovery, 1.51; 95% CI, 1.10 to 2.08). The 28-day mortality was 5.1% in the combination group and 7.8% in the control group (hazard ratio for death, 0.65; 95% CI, 0.39 to 1.09). Serious adverse events were less frequent in the combination group than in the control group (16.0% vs. 21.0%; difference, -5.0 percentage points; 95% CI, -9.8 to -0.3; P = 0.03), as were new infections (5.9% vs. 11.2%; difference, -5.3 percentage points; 95% CI, -8.7 to -1.9; P = 0.003). CONCLUSIONS: Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04401579.). Twit Text FOAVip Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 ????N Engl J Med http://www.kidney.de/pget.php?&tw=1&pmid=33306283 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33306283 #FOAvip English Wikipedia <ref>{{Cite pmid|33306283}}</ref> Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 #MMPMID33306283 Kalil AC; Patterson TF; Mehta AK; Tomashek KM; Wolfe CR; Ghazaryan V; Marconi VC; Ruiz-Palacios GM; Hsieh L; Kline S; Tapson V; Iovine NM; Jain MK; Sweeney DA; El Sahly HM; Branche AR; Regalado Pineda J; Lye DC; Sandkovsky U; Luetkemeyer AF; Cohen SH; Finberg RW; Jackson PEH; Taiwo B; Paules CI; Arguinchona H; Erdmann N; Ahuja N; Frank M; Oh MD; Kim ES; Tan SY; Mularski RA; Nielsen H; Ponce PO; Taylor BS; Larson L; Rouphael NG; Saklawi Y; Cantos VD; Ko ER; Engemann JJ; Amin AN; Watanabe M; Billings J; Elie MC; Davey RT; Burgess TH; Ferreira J; Green M; Makowski M; Cardoso A; de Bono S; Bonnett T; Proschan M; Deye GA; Dempsey W; Nayak SU; Dodd LE; Beigel JH N Engl J Med 2021[Mar]; 384 (9): 795-807 PMID33306283show ga BACKGROUND: Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. METHODS: We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir ( |*COVID-19 Drug Treatment[MESH] |Adenosine Monophosphate/adverse effects/*analogs & derivatives/therapeutic use[MESH] |Adult[MESH] |Aged[MESH] |Alanine/adverse effects/*analogs & derivatives/therapeutic use[MESH] |Antiviral Agents/adverse effects/*therapeutic use[MESH] |Azetidines/adverse effects/*therapeutic use[MESH] |COVID-19/mortality/therapy[MESH] |Double-Blind Method[MESH] |Drug Therapy, Combination[MESH] |Female[MESH] |Hospital Mortality[MESH] |Hospitalization[MESH] |Humans[MESH] |Janus Kinase Inhibitors/adverse effects/therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Oxygen Inhalation Therapy[MESH] |Purines/adverse effects/*therapeutic use[MESH] |Pyrazoles/adverse effects/*therapeutic use[MESH] |Respiration, Artificial[MESH] |Sulfonamides/adverse effects/*therapeutic use[MESH]Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 (epmc).pdf DeepDyve Pubget Overpricing